Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Citigroup

Gilead Sciences (NASDAQ:GILD) had its target price upped by Citigroup from $165.00 to $188.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a research report on Friday, October 23rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $184.00 price objective on shares of Gilead Sciences in a research report on Friday. Finally, Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Gilead Sciences Stock Up 3.1%

Gilead Sciences stock opened at $170.68 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences has a 1-year low of $114.02 and a 1-year high of $175.65. The company’s 50-day moving average is $150.87 and its 200 day moving average is $139.79.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter last year, the firm earned $2.47 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. PFS Partners LLC raised its position in shares of Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $25,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth $29,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences during the second quarter valued at about $25,000. Finally, Toth Financial Advisory Corp boosted its position in Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.